D&D Pharmatech Inc. (KOSDAQ:347850)
 277,000
 +55,000 (24.77%)
  Oct 31, 2025, 1:40 PM KST
D&D Pharmatech Revenue
D&D Pharmatech had revenue of 924.56M KRW in the quarter ending June 30, 2025, a decrease of -60.09%. This brings the company's revenue in the last twelve months to 9.33B, down -29.52% year-over-year. In the year 2024, D&D Pharmatech had annual revenue of 11.44B, down -38.77%.
Revenue (ttm) 
 9.33B
Revenue Growth 
 -29.52%
P/S Ratio 
 258.23
Revenue / Employee 
 444.44M
Employees 
 21
Market Cap 
2.41T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 11.44B | -7.24B | -38.77% | 
| Dec 31, 2023 | 18.68B | 18.07B | 2,958.97% | 
| Dec 31, 2022 | 610.57M | -753.54M | -55.24% | 
| Dec 31, 2021 | 1.36B | - | - | 
| Dec 31, 2020 | - | - | - | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| Samsung Biologics | 5.03T | 
| Celltrion | 3.75T | 
| Yuhan | 2.17T | 
| SK Biopharmaceuticals | 620.28B | 
| PharmaResearch | 449.81B | 
| Sam Chun Dang Pharm. | 215.10B | 
| ALTEOGEN | 158.06B | 
| LigaChem Biosciences | 148.28B |